The changes introduced within E2B(R3) are not solely technical, they have a significant impact on the overall pharmacovigilance processes. In this post we look at some of regulatory changes specifically called out by the EMA.

Read more

Over recent years there has been a significant increase in the regulations surrounding the safety of pharmaceutical products. Regardless of size or geolocation, all life science companies are obliged to collect, investigate and monitor adverse events related to their entire portfolio of medicinal products. Over the years, various legislation has defined the process of adverse event reporting, and most recently E2B(R3) introduces the latest iteration to the ICH E2B technical specification.

Read more

Come May 5, 2017, all Drug Master File (DMF) submissions will need to be filed electronically with FDA in an eCTD format, or they will be rejected. This upcoming regulation is expected to promote efficiency of the DMF review process, but are companies ready to comply? Learn more about the new regulation and how to navigate the transition in order to remain compliant.

Read more

The idea is simple - to remain compliant, life sciences organizations need to demonstrate that they are in control of their business, processes and data. Whatever the regulation, the higher the degree of internal data governance, the lower the cost and effort associated with compliance. Non-compliance is not an option and regulators do not hesitate to impose fines costing millions of dollars or withdraw products from the market for failure to do so.

Read more

In this post, the second in our series on IDMP, we take a closer look at the ISO standards that make up the new regulation. IDMP is a series of five different ISO standards consisting of four technical specifications and one technical report. The behind the scenes the creation of these has been a major collaborative effort involving medicinal experts from 32 participating and 27 observing countries.

Read more

Starting from next year, companies that have pharmaceutical products registered within the EU will need to comply with the new Identification of Medicinal Products (IDMP) standard. With other regional regulatory authorities expected to follow soon this series of posts takes a closer look at the IDMP standard and how best to implement it within your organization.  

Read more

Copyright ©  2017  EXTEDO. All rights reserved.